Synjardy XR 5 mg/1

Synjardy XR 5 mg/1 is an extended-release tablet combining empagliflozin and metformin hydrochloride. It is designed to help manage blood sugar levels in adults with type 2 diabetes. This medication is suitable for those who need dual therapy to control their condition.

Synjardy XR 5 mg/1 is primarily used to improve glycemic control in adults with type 2 diabetes. It works by combining two active ingredients: empagliflozin, which helps the kidneys remove excess glucose from the body, and metformin hydrochloride, which reduces the amount of sugar released by the liver and improves the body's response to insulin. This combination therapy is often prescribed when diet and exercise alone are not enough to manage blood sugar levels effectively.

Common effects of Synjardy XR 5 mg/1 may include symptoms such as nausea, diarrhea, and headache. Some individuals might experience urinary tract infections or low blood sugar levels, especially when starting the medication or adjusting the dose. It is important to monitor for any unusual symptoms and consult a healthcare provider if they persist or worsen.

Synjardy XR 5 mg/1 should be taken exactly as prescribed. It is important to stay hydrated and maintain a balanced diet while using this medication. Patients with kidney problems or a history of lactic acidosis should discuss their medical history with a healthcare provider before starting this treatment. Always follow the advice of a healthcare professional regarding the use of this medication.

Synjardy XR 5 mg/1 may interact with certain medications, including diuretics, blood pressure medications, and other drugs that affect kidney function. Alcohol can increase the risk of lactic acidosis, so it is advisable to limit alcohol consumption while taking this medication. Always inform your healthcare provider about all the medications you are taking to avoid potential interactions.